TRANSVAC

Background Vaccines are one of the most successful and cost-effective public health tools for disease prevention. However, their development is time-consuming and complex, requiring a combination of specialised skills and technical capacities not readily available at a single organisation. In order to facilitate access to these skills and capacities, and to promote collaborations in the European vaccine landscape - aiming thereby to accelerate the development of safe, effective and affordable vaccines - the EC, in the context of the Horizon 2020 Framework Programme, has recently funded “TRANSVAC2”, a European vaccine research and development (R&D) infrastructure. TRANSVAC2 builds upon the success of TRANSVAC, the European Network of Vaccine Research and Development funded under the EC's previous Framework Programme (FP7). TRANSVAC made significant contributions to the European vaccine development landscape, providing scientific-technical services to more than 29 vaccine projects and developing a roadmap for the establishment of a sustainable European vaccine R&D. Starting in February 2022, TRANSVAC joined the ISIDORe network, allowing the consortium to continue providing services and harmonize with other research infrastructures.